Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 12 of 12 publications.
Skip to main content
McKenna SP, Doughty N, Pepke-Zaba J, Meads D, Doward LC. Development of patient-reported outcome measures for pulmonary arterial hypertension. Poster presented at the 2003 ISPOR 6th Annual European Congress; November 2003. Barcelona, Spain. [abstract] Value Health. 2003 Nov; 6(6):671.
Doward LC, McKenna SP, Meads DM. Development of the herpes outbreak impact questionnaire (HOIQ). Poster presented at the 2003 ISPOR 6th Annual European Congress; November 2003. Barcelona, Spain. [abstract] Value Health. 2003 Nov; 6(6):760-1.
Doward LC, McKenna SP, Meads DM. Development of the herpes outbreak impact questionnaire (HOIQ). Poster presented at the 10th Annual Conference of the International Society for Quality of Life Research (ISQOL); November 2003. [abstract] Qual Life Res. 2003 Nov; 12(7):862.
Quam JP, Ackerman SJ, Mordin MM, Bassett LW. Conspicuity and characterization of findings on computed radiography for mammography vs. screen-film mammography: results from a prospective clinical trial. Poster presented at the 89th Scientific Assembly and Annual Meeting of the Radiology Society of North America; November 2003.
DeMuro-Mercon CJ, Gonce C, Lewis SA, Altarac D, O'Keefe S, Bachmann S. The electronic patient reported outcome (e-PRO): compliance procedures and regulatory applicability. Poster presented at the Drug Information Association; October 2003.
Trump DL, Wilding G, Miller K, Small E, Soulie P, Trachtenberg J, Raabe N, Heyes AE, Das-Gupta A. Pilot trials of ZD1839 ('Iressa'), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with mitoxantrone/prednisolone or docetaxel/estramustine in patients with hormone-refractory prostate cancer. Presented at the American Urology Association; April 2003. Chicago, IL.
Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003 Feb 1;4(2):131-9.
Doward LC, Spoorenberg A, Whalley D, Cook SA, Helliwell PS, Kay LJ, McKenna SP, Tennant A, van der Heijde D, Chamberlain MA. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003 Jan 1;62(1):20-6.
McLeod LD, Fehnel SE, Brandman J, Symonds T. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. Pharmacoeconomics. 2003 Jan 1;21(15):1069-79.
DeMuro-Mercon CJ, Lewis SA, Gonce C. Old relationships, new technologies: partnering with your clinical sites to make an electronic patient reported outcome (e-PRO) work for diary and questionnaire data. Poster presented at the Drug Information Association; 2003.
Nadjar A, Martin AR, Giroudet C, Lewis S, Conway K, Lindley C, Olver I. Multi-national phase III trials of aprepitant for the prevention of cinv: translation and linguistic validation of an emesis diary and patient questionnaire into 22 languages. Presented at the 2003 American Society of Clinical Oncology Annual Meeting, Abstract No. 3158; January 1, 2003. Chicago, IL.
Lovas K, Kalo Z, McKenna SP, Whalley D, Pentek M, Genti G. Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. Health Policy (New York). 2003 Jan 1;63(1):20.